Bianca Weinstock-Guttman
SUNY Buffalo · Jacob's Neurological Institute · University at Buffalo
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bianca Weinstock-Guttman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:29 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT03046251 · Natalizumab in Preventing Post-partum Relapses in Multiple SclerosisState University of New York at Buffalo · completed · Multiple Sclerosis · principal investigator
- Ph4NCT02775110 · Natalizumab Temporary Discontinuation StudyUniversity at Buffalo · completed · Multiple Sclerosis · principal investigator
- Ph2/Ph3NCT02006160 · Effects of Dalfampridine on Cognition in Multiple SclerosisState University of New York at Buffalo · completed · Multiple Sclerosis · principal investigator
- Ph2NCT00986960 · Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)University at Buffalo · withdrawn · Multiple Sclerosis · principal investigator
- Ph4NCT00304291 · A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)State University of New York at Buffalo · completed · Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:29 UTC. The ranking covers the 200 most relevant of 56 PubMed records, and a shared surname and initials can bring in a namesake. All 56 on PubMed
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.N Engl J Med · 20061,049 citationsRCR 25.5
- Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.Arch Neurol · 2004306 citationsRCR 9.2
- Eight-year follow-up study of brain atrophy in patients with MS.Neurology · 2002295 citationsRCR 7.3
- 260 citationsRCR 6.1
- The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.Neurology · 2007249 citationsRCR 6.5
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.N Engl J Med · 2018230 citationsRCR 9.7
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.J Neurol · 2009187 citationsRCR 5.6
- MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.Neurology · 2014154 citationsRCR 5.7
- 150 citationsRCR 4.2
- Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients.Prostaglandins Leukot Essent Fatty Acids · 2005148 citationsRCR 3.9